IP Library Granted Patent US 9,072,759
Granted Patent B2
US 9,072,759 · App. 13/125,550 · Granted Jul 7, 2015

Biodefenses using triazole-containing macrolides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,072,759
App. No.
13/125,550
Granted
Jul 7, 2015
Kind
B2
Abstract

Use of macrolide and ketolide antibiotics for the treatment of acute exposure and diseases caused by biodefense pathogens is described.

Claims (49)

1. A method for acute-exposure treatment of a patient exposed to one or more organisms selected from the group consisting of Bacillus anthracis and Burkholderia mallei , and combinations thereof; the method comprising the step of administering to the patient an effective amount of one or more compounds of the formula

or pharmaceutically acceptable salt thereof, wherein:

R 10 is hydrogen or acyl;

X and Y are taken together with the attached carbon to form carbonyl;

V is C(O), C(═NR 11 ), CH(NR 12 , R 13 ), or N(R 14 )CH 2 ; where N(R 14 ) is attached to the C-10 carbon; where R 11 is hydroxy or alkoxy; R 12 and R 13 are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted, and dimethylaminoalkyl, acyl, sulfonyl, ureido, and carbamoyl; R 14 is hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted, or dimethylaminoalkyl, acyl, sulfonyl, ureido, or carbamoyl;

W is H, F, Cl, Br, I, or OH;

A is CH 2 , C(O), C(O)O, C(O)NH, S(O) 2 , S(O) 2 NH, or C(O)NHS(O) 2 ;

B is C 0 -C 10 alkylene, C 2 -C 10 alkenylene, or C 2 -C 10 alkynylene; and

C is hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted, or acyl, acyloxy, sulfonyl, ureido, or carbamoyl;

or a pharmaceutical composition thereof further comprising one or more pharmaceutically acceptable carriers, diluents, or excipients, or a combination thereof.

2. A method for treating a patient with a disease caused at least in part by one or more organisms selected from the group consisting of Bacillus anthracis and Burkholderia mallei , and combinations thereof; the method comprising the step of administering to the patient an effective amount of one or more compounds of the formula

or pharmaceutically acceptable salt thereof, wherein:

R 10 is hydrogen or acyl;

X and Y are taken together with the attached carbon to form carbonyl;

V is C(O), C(═NR 11 ), CH(NR 12 , R 13 ), or N(R 14 )CH 2 ; where N(R 14 ) is attached to the C-10 carbon; where R 11 is hydroxy or alkoxy; R 12 and R 13 are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted, and dimethylaminoalkyl, acyl, sulfonyl, ureido, and carbamoyl; R 14 is hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted, or dimethylaminoalkyl, acyl, sulfonyl, ureido, or carbamoyl;

W is H, F, Cl, Br, I, or OH;

A is CH 2 , C(O), C(O)O, C(O)NH, S(O) 2 , S(O) 2 NH, or C(O)NHS(O) 2 ;

B is C 0 -C 10 alkylene, C 2 -C 10 alkenylene, or C 2 -C 10 alkynylene; and

C is hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted, or acyl, acyloxy, sulfonyl, ureido, or carbamoyl;

or a pharmaceutical composition thereof further comprising one or more pharmaceutically acceptable carriers, diluents, or excipients, or a combination thereof.

3. The method of claim 1 wherein R 10 is hydrogen.

4. The method of claim 1 wherein A is CH 2.

5. The method of claim 1 wherein B is (CH 2 ) n , where n is an integer from 1-5.

6. The method of claim 1 wherein C is aryl or heteroaryl, each of which is optionally substituted.

7. The method of claim 1 wherein C is 3-aminophenyl or 3-pyridinyl.

8. The method of claim 1 wherein V is C(O).

9. The method of claim 1 wherein W is H or F.

10. The method of claim 1 wherein W is F.

11. The method of claim 1 wherein V is C(O); and W is F.

12. The method of claim 1 wherein A is CH 2 , B is (CH 2 ) n , and n is an integer from 2-4.

13. The method of claim 12 wherein C is 3-aminophenyl.

14. The method of claim 13 wherein V is C(O).

15. The method of claim 14 wherein W is F.

16. The method of claim 15 wherein n is 3.

17. The method of claim 16 wherein R 10 is hydrogen.

18. The method of claim 1 wherein the compound is of the formula

or a pharmaceutically acceptable salt thereof.

19. The method of claim 1 wherein the compound is of the formula

where HX is a pharmaceutically acceptable salt forming acid.

20. The method of claim 19 wherein HX is selected from the group consisting of hydrochloric acid, tartaric acid, and combinations thereof.

21. The method of claim 1 wherein the compound is of the formula

22. The method of claim 2 wherein the compound is of the formula

or a pharmaceutically acceptable salt thereof.

23. The method of claim 2 wherein the compound is of the formula

where HX is a pharmaceutically acceptable salt forming acid.

24. The method of claim 23 wherein HX is selected from the group consisting of hydrochloric acid, tartaric acid, and combinations thereof.

25. The method of claim 2 wherein the compound is of the formula

26. The method of claim 18 wherein the organism is Bacillus anthracis.

27. The method of claim 22 wherein the organism is Bacillus anthracis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
RELEASE OF SECURITY INTEREST Recorded Jun 4, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: CEMPRA PHARMACEUTICALS, INC.
Reel/Frame 049363/0706 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →